Amgen Inc. $AMGN Stock Holdings Increased by Sumitomo Mitsui Financial Group Inc.

Posted by Max Byerly on Jun 12th, 2026

Sumitomo Mitsui Financial Group Inc. increased its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,123 shares of the medical research company’s stock after purchasing an additional 2,344 shares during the quarter. Sumitomo Mitsui Financial Group Inc.’s holdings in Amgen were worth $25,570,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. High Note Wealth LLC boosted its position in shares of Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares during the period. TAGStone Capital Inc. lifted its position in Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after purchasing an additional 28 shares during the period. Verus Capital Partners LLC lifted its position in Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after purchasing an additional 28 shares during the period. West Family Investments Inc. lifted its position in Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after purchasing an additional 30 shares during the period. Finally, Viawealth LLC lifted its position in Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after purchasing an additional 30 shares during the period. 76.50% of the stock is currently owned by institutional investors.

More Amgen News

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen presented new Phase 3 VESALIUS-CV data showing Repatha significantly reduced cardiovascular risk in high-risk diabetes patients, strengthening the case for its cardio-metabolic franchise. Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now
Positive Sentiment: Investor coverage remains bullish, with articles highlighting Amgen as a potential value stock and pointing to attractive valuation metrics versus expected earnings growth. Is Amgen Inc. (AMGN) A Good Stock To Buy Now?
Positive Sentiment: Amgen updated investors on its Phase 3 MARITIME-SWITCH trial, which targets GLP-1 switchers in obesity, supporting its strategy to win share in a rapidly expanding market. Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
Neutral Sentiment: Several market commentary pieces discussed Amgen as a large-cap value or healthcare exposure idea, but these are mostly sentiment-driven rather than immediate fundamentals. Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Negative Sentiment: Recent trading-day coverage noted Amgen underperformed the broader market, suggesting some short-term profit-taking or volatility even as the longer-term story improves. Amgen Inc. stock underperforms Wednesday when compared to competitors

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Stock Up 4.8%

Shares of NASDAQ AMGN opened at $354.06 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The company has a market cap of $191.09 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 3.39 and a beta of 0.42. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29. The stock has a 50-day moving average price of $340.94 and a two-hundred day moving average price of $345.65.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on AMGN shares. Royal Bank Of Canada upped their price objective on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Argus cut their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research report on Wednesday, April 8th. Morgan Stanley upped their price objective on shares of Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, Daiwa Securities Group cut their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and an average price target of $354.12.

Get Our Latest Stock Report on Amgen

Amgen Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.